Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 4/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21653719 | 1.00 | NOS1 (0.39) | NOS1IDO1ROCK1AXLESR1 | |
| SCHEMBL25230509 | 0.82 | TRPA1 (0.42) | NOS1IDO1ROCK1AXLESR1 | |
| SCHEMBL27188140 | 0.80 | BRD4 (0.39) | NOS1IDO1ROCK1AXLESR1 | |
| SCHEMBL29712207 | 0.80 | BRD4 (0.39) | NOS1IDO1ROCK1AXLESR1 | |
| SCHEMBL29376674 | 0.79 | IDO1 (0.50) | NOS1IDO1AXLBRAFMETAP2 | |
| SCHEMBL189955 | 0.79 | IDO1 (0.50) | NOS1IDO1AXLBRAFMETAP2 | |
| SCHEMBL19785593 | 0.77 | NOS1 (0.39) | NOS1UCHL1 | |
| SCHEMBL3496375 | 0.77 | NOS1 (0.36) | NOS1UCHL1BRAF | |
| SCHEMBL16971684 | 0.77 | METAP2 (0.42) | NOS1IDO1BRAFMETAP2 | |
| SCHEMBL26920428 | 0.76 | P2RX7 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20220363693-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363693-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN9, PTPN7 | NOS1 4203/4885IDO1 2920/4885ROCK1 279/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | NOS1 3876/4885IDO1 2302/4885ROCK1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.